For patients with allergic rhinitis, twice-daily azelastine plus fluticasone cut nasal symptoms ... all treatments were administered as one spray twice daily to preserve blinding.
An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
Corstasis to present pivotal trial data on Bumetanide Nasal Spray at AHA 2024, highlighting safety, and efficacy. #AHA2024. Home is where the heart is ...
Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for ...
Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...
The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key ...
An alternative, nasal spray, formulation has been developed that demonstrates good efficacy, high tolerability and a very fast onset of action. This study assessed the pharmacokinetics and ...
ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS ...
Investor's Business Daily on MSN4d
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal SprayARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.
Amanda Gardner is a freelance health reporter whose stories have appeared in cnn.com, health.com, cnn.com, WebMD, HealthDay, Self Magazine, the New York Daily News, Teachers & Writers Magazine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback